Using the CODEEVOLVER® directed evolution platform to create improved enzymes for molecular diagnostics
September 24-28, 2017
Using advanced enzyme engineering technology, Codexis has developed practical, green manufacturing processes for a range of pharmaceutical intermediates and APIs, biologic drug discovery and food ingredients. Our enzyme engineering technology has produced a diverse array of enzymes that are operationally equivalent and complementary to the “standard” catalysts in the chemists’ tool box. Parallel optimization of enzyme, enzyme formulation, and chemical process continues to push the catalyst cost contribution lower, expanding the application of custom-made enzymes into larger volume opportunities.
Recently, Codexis announced that it will offer high-performance enzymes for customers using next generation sequencing (NGS) for in vitro molecular diagnostic applications. Historically, NGS workflows relied on modestly engineered enzymes. As NGS is being pushed into new, more demanding applications, such as liquid biopsy and personalized medicine samples, more capable enzymes are required. Example of engineering an enzyme with improved analytical efficiency, processivity and fidelity while also reducing bias in preparation steps for NGS using the CodeEvolver directed evolution platform will be presented
Vesna Mitchell, Sandy Gomes, Nikki Dellas, David Elgart, Judy Viduya, Jonathan Vroom, and Matt Miller, "Using the CODEEVOLVER® directed evolution platform to create improved enzymes for molecular diagnostics" in "Enzyme Engineering XXIV", Pierre Monsan, Toulouse White Biotechnology, France Magali Remaud-Simeon, LISBP-INSA, University of Toulouse, France Eds, ECI Symposium Series, (2017). http://dc.engconfintl.org/enzyme_xxiv/173